Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib

Sorafenib is the first systemic therapy to demonstrate survival benefit in advanced hepatocellular carcinoma (HCC) in randomized controlled trials with rigorous patient selection. Neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with poor survival in various solid tumors. Our aim is to evaluate the prognostic role of NLR in HCC patients treated with sorafenib. A total of 105 advanced HCC patients treated with sorafenib were retrospectively reviewed, and relevant data from the clinical records were collected. Univariate and multivariate analysis were carried out to identify factors associated with survival. The median age of the cohort was 59.7 years, and 84.8 % were Child-Pugh class A, and 86.7 % had ECOG performance status 0 or 1. Median duration of sorafenib treatment was 100 days. Median overall survival (OS) of the entire cohort was 8.03 months. Median OSwas 5.23 months (95 % CI 2.96-7.50 months) and 10.05 months (95 % IC 2.52-18.47 months) for patients with NLR>3.5 and NLR <= 3.5, respectively (p = 0.002). Alpha-fetoprotein [1,030 ng/mL and serum albumin B3.8 g/dL were also associated with worse prognosis (p = 0.006 and p = 0.042, respectively). The subgroup of patients with high alpha-fetoprotein, low albumin and NLR>3.5 had median OS of 1.7 months, whereas the subgroup with none of these parameters had median OS of 16.5 months (p< 0.001). NLR affects survival in advanced HCC patients treated with sorafenib. Selecting HCC patients based on the laboratorial features may improve the therapeutic effectiveness of sorafenib.

Palavras-chave

Hepatocellular cancer, Sorafenib tosylate, Neutrophil count, Lymphocyte count, Prognosis

URI

https://observatorio.fm.usp.br/handle/OPI/8389

Referências

An X, 2010, BIOMARKERS, V15, P516, DOI 10.3109/1354750X.2010.491557
Baek KK, 2011, ONCOLOGY-BASEL, V80, P167, DOI 10.1159/000327591
Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
Gomez D, 2008, WORLD J SURG, V32, P1757, DOI 10.1007/s00268-008-9552-6
Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
Johnson P J, 2001, Clin Liver Dis, V5, P145, DOI 10.1016/S1089-3261(05)70158-6
Kishi Y, 2009, ANN SURG ONCOL, V16, P614, DOI 10.1245/s10434-008-0267-6
Kuang DM, 2011, J HEPATOL, V54, P948, DOI 10.1016/j.jhep.2010.08.041
Limaye AR, 2013, HEPATOL RES, V43, P757, DOI 10.1111/hepr.12019
Llovet JM, 2012, CLIN CANCER RES, V18, P2290, DOI 10.1158/1078-0432.CCR-11-2175
Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
Llovet Josep M, 2004, Liver Transpl, V10, pS115, DOI 10.1002/lt.20034
Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
McNally ME, 2013, ANN SURG ONCOL, V20, P923, DOI 10.1245/s10434-012-2639-1
Motomura T, 2013, J HEPATOL, V58, P58, DOI 10.1016/j.jhep.2012.08.017
NOMURA F, 1989, CANCER, V64, P1700, DOI 10.1002/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z
Ohtani H, 2007, CANC IMMUN, V21, P4
Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
Yamanaka T, 2007, ONCOLOGY-BASEL, V73, P215, DOI 10.1159/000127412
Zhang Z, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-41

Coleções

Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/61
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo